C
LINICAL TRIALS ARE THE CENtralmeansbywhichpreventive, diagnostic, and therapeutic strategiesareevaluated, 1 butthe US clinical trials enterprise has been marked by debate regarding funding prioritiesforclinicalresearch,thedesignand interpretation of studies, and protections forresearchparticipants. [2] [3] [4] Untilrecently, however, we have lacked tools for comprehensively assessing trials across the broader US clinical trial enterprise.
In 1997, Congress mandated the creation of the ClinicalTrials.gov registry to assistpeoplewithseriousillnessesingaining access to trials. 5 In September 2004, the International Committee of Medical Journal Editors (ICMJE) announced a policy, which took effect in 2005, of requiring registration of clinical trials as a prerequisite for publication. 6, 7 The Food andDrugAdministrationAmendmentAct (FDAAA) 8 expanded the mandate of ClinicalTrials.gov to include most nonphase 1 interventional drug and device trials, with interventional trials defined as "studies in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions" 9 (eTable 1, available at http://www.jama.com). The law obliges sponsors or their designees to register trials and record key data elements (effective September 27, 2007) , report basic results (September 27, 2008) , and report adverse events (September 27, 2009). 10 Recent work 11, 12 highlights the inadequate evidence base of current practice, in which less than 15% of major guideline recommendations are based on high-quality evidence, often defined as evidence that emanates from trials with appropriate designs; sufficiently large sample sizes; and appropriate, validated outcome measures, 13, 14 as well as oversight by institutional review boards and data moni- toring committees (DMCs) to protect participants and ensure the trial's integrity. 14 In this article, we examine fundamental characteristics of interventional clinical trials in 3 major therapeutic areas contained in the registry (cardiovascular, mental health, and oncology), focusing on study characteristics (data elements reported in trial registration) that are desirable for generating reliable evidence from clinical trials, including factors associated with use of DMCs, randomization, and blinding.
METHODS
The methods used by ClinicalTrials.gov to register clinical studies have been described previously. [15] [16] [17] Briefly, sponsors and investigators from around the world enter data through a web-based data entry system. The country address of each facility (ie, a site that can potentially enroll participants) was used to group sites into regions according to rubrics used by ClinicalTrials.gov. 18 (Individual countries included in each region are available.) The sample we examined includes studies registered to comply with legal obligations, as well as those registered voluntarily to meet ICMJE requirements or for other reasons. Similarly, data for registered studies include both mandatory and optional elements. Over time, the types, definitions, and optional vs mandatory status of data elements have changed. Mandatory and optional data elements for registration as of August 2011 are shown in eAppendix 1.
ClinicalTrials.gov Data Set
We downloaded an XML data set comprising all 96 346 clinical studies registered with ClinicalTrials.gov as of September 27, 2010-1 decade after the registry's launch and 3 years after enactment of the FDAAA. We loaded the data set into a relational database (Oracle RDBMS version 11.1g, Oracle Corporation) to facilitate aggregate analysis. This resource, the Database for Aggregate Analysis of ClinicalTrials.gov (AACT), as well as data definitions, and comprehensive data dictionaries, is available at the Clinical Trials Transformation Initiative website.
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Our analysis was restricted to interventional studies registered with ClinicalTrials.gov between October 2007 and September 2010. To identify interventional studies, we used the "study type" field from the ClinicalTrials.gov registry, which included the following choices: interventional, observational, expanded access, and not available (NA) (eAppendix 1). Interventional trials were defined as "studies in human beings in which individuals are assigned by an investigator based on a protocol to receive specific interventions." In this study, the terms clinical trial, interventional trial, and interventional study are synonomous. Interventional studies were regrouped within the downloaded, derivative database according to the 3 clinical specialties-cardiovascular, oncology, and mental health-that together encompass the largest number of disability-adjusted life-years lost in the United States. 20 For this regrouping, we used submitted disease condition terms and Medical Subject Heading (MeSH) terms generated by a National Library of Medicine (NLM) algorithm to develop a methodology to annotate, validate, adjudicate, and implement disease condition terms (MeSH and non-MeSH) to create specialty data sets.
A subset of the 2010 MeSH thesaurus from the NLM 21 and a list of nonMeSH disease condition terms provided by data submitters that appeared in 5 or more interventional studies in the analysis data set were reviewed and annotated by clinical specialists at Duke University Medical Center (eAppendix 2). Terms were annotated according to their relevance to a given specialty (Y = relevant, N = not relevant). Specialty data sets were created and the results of algorithmic classifications were validated by comparison with classifications based on manual review. Clinical trials were classed according to date registered and by interventional status. Details regarding the creation of these specialty data sets are provided in an article describing the study methodology. 22 Within these specialty data sets, a few data elements are missing because of limitations in the data set or logistical problems in obtaining analyzable information. Specifically, the data element "human subject review" is not present in the public download, and data regarding primary outcomes and oversight authority are not readily analyzable because of the presence of freetext values.
Analytical Methods
Clinical trial characteristics were first assessed overall, by interventional trials, and by 2 temporal subsets: October 2004 through September 2007 and October 2007 through September 2010. The percentage of trials registered before and after enrollment of the first participant was also determined by comparing the date of registration to the date that the first participant was enrolled. Other assessments included clinical trial characteristics, enrollment characteristics, funding source, and number of study sites for all clinical trials vs cardiovascular, mental health, and oncology trials for the latter time period (October 2007-September 2010). Funding sources included industry, NIH, other US federal (excluding NIH), and other. Frequencies and percentages are provided for categorical characteristics; medians and interquartile ranges (IQRs) are provided for continuous characteristics.
Logistic regression analysis was performed to calculate adjusted odds ratios (ORs) with Wald 95% confidence intervals for factors associated with trials that report use of DMCs, randomization, and blinding. A full model containing 9 prespecified characteristics was developed. The first of these was lead sponsor, which the NLM defines as the primary organization that oversees study implementation and is responsible for conducting data analysis. 19 Collaborators are defined as other organizations (if any) that provide additional support, including funding, design, implementation, data analysis, and reporting. The sponsor (or designee) is responsible for confirming all CLINICAL TRIALS REGISTERED IN CLINICALTRIALS.GOV collaborators before listing them. ClinicalTrials.gov stores funding organization information in 2 data elements: lead sponsor and collaborator. The NLM classifies submitted agency names in these data elements as industry, NIH, US federal (excluding NIH), or other. We derived probable funding source from the lead sponsor and collaborator fields using the following algorithm: if the lead sponsor was from industry, or the NIH was neither a lead sponsor nor collaborator and at least 1 collaborator was from industry, then the study was categorized as industry funded. If the lead sponsor was not from industry, and NIH was either a lead sponsor or a collaborator, then the study was categorized as NIH funded. Otherwise, if the lead sponsor and collaborator fields were nonmissing, then the study was considered to be funded by other.
Also included in the model were phase (0, 1, 1/2, 2, 2/3, 3, 4, NA); number of participants; trial specialtycardiovascular, oncology, or mental health (yes/no); trial start year; intervention type (procedure/device, drug or biological, behavioral, dietary supplement, other); and primary purpose (treatment, prevention, diagnostic, other). For the purposes of this modeling, studies reporting multiple intervention types were categorized in the following hierarchy: 1, procedure/ device; 2, drug/biological; 3, behavioral; 4, dietary supplement; 5, other. Studies missing a response to any of the data elements used in the model were excluded. The model predicting trials with DMC was also run in 2 additional ways: (1) assuming that those trials missing a response to the question regarding DMC did in fact have a DMC, and (2) A decline in the numbers of missing data elements occurred for some characteristics. The rate of registered trials not reporting use of DMCs decreased from 57.9% to 18% between the 2 time periods; not reporting either enrollment number or type (anticipated or actual) decreased from 33.8% to 1.8%; not reporting randomization decreased from 5.6% to 4.2%; and not reporting blinding decreased from 3.5% to 2.7%. The rate of missing data for primary purpose increased from 4.6% to 6.8% during these periods. The proportion of trials reporting an NIH lead sponsor decreased from 6.3% to 2.7% during the during the 2 periods, and the proportion of trials with at least 1 North American research site decreased from 61.9% to 57.5%. Other characteristics have not changed substantially.
The proportion of trials registered before beginning participant enrollment increased over the 2 time periods: from 33% (9041/27 667) in The majority of clinical trials were small in terms of numbers of participants. Overall, 96% of these trials had an anticipated enrollment of 1000 or fewer participants and 62% had 100 or fewer participants (eFigure). The median number of participants per trial was 58 (IQR, 27-161) for completed trials and 70 (IQR, for trials that have been registered but not completed.
TABLE 2 shows selected characteristics of all interventional trials registered from October 2007 through September 2010 (n = 40 970), as well as characteristics for oncology, cardiovascular, and mental health trials compared with all other trials. Of these 3 categories, oncology trials were most numerous (n=8992, 21.9%) and comprised the largest proportion of trials listed as currently recruiting: 31.5% vs 9.3% and 10% for cardiovascular and mental health trials, respectively. Oncology trials also constituted the largest proportion of trials that were active but not yet recruiting (25.8% vs 7.4% for cardiovascular and 7.5% for mental health) and that were oriented toward treatment (25.7% vs 8% for cardiovascular and 9.6% for mental health). Among trials oriented toward prevention, cardiovascular trials comprised the largest group: 10.4% vs 8.1% for oncology and 5.9% for mental health. Cardiovascular trials also accounted for the largest proportion of trials assessing medical devices: 20.2% vs 7.0% for oncology and 3.8% for mental health. As expected, among trials incorporating behavioral interventions, mental health trials were most common: 33.4% vs 8.1% for oncology and 7.2% for cardiovascular.
Enrollment and design characteristics for all interventional trials registered from October 2007 through September 2010 are displayed in TABLE 3. There was heterogeneity in median anticipated trial size according to specialty. Cardiovascular trials (median anticipated enrollment, 100; IQR, 42-280) tended to be nearly twice as large as oncology trials (median, 54; IQR, 30-120), with mental health trials (median, 85; IQR, 40-200) residing between these 2. Cardiovascular and mental health trials were more oriented toward later-phase research (ie, phases 3 and 4) while oncology trials displayed a higher relative proportion of earlier-phase trials (ie, phases 0 through 2). Trials restricted to women CLINICAL TRIALS REGISTERED IN CLINICALTRIALS.GOV There were also differences in age distribution among therapeutic areas. Mental health trials were most likely to permitinclusionofchildren(17.9%vs11.3% for oncology and 10.5% for cardiovascular) but were also most likely to exclude elderly participants: 56% of mental health trials excluded participants older than 65 years compared with 8.1% for oncology and 13.3% for cardiovascular.
Geographical differences were also apparent. Cardiovascular trials showed the smallest proportion of studies with at least 1 North American research site (47.9%, vs 65.1% for oncology and 69.1% for mental health) and the most substantial proportion of trials with at least 1 European site (39.9% vs 27.6% and 20.9%, respectively).
Differences in trial design were also evident among therapeutic areas ( a Allowable values for this field are actual and anticipated. "Primary completion date" denotes the date that the final research participant was examined or received an intervention for the purposes of final collection of data for the primary outcome, whether the clinical trial concluded according to the prespecified protocol or was terminated. b Percentages may not sum to 100% as categories are not mutually exclusive. There were small differences in reporting of blinding or randomization by different lead sponsor organizations. For example, trials in which a US federal agency (excluding the NIH) or another sponsor was the lead sponsor were less likely to report use of blinding (adjusted OR, 0.65; 95% CI, 0.51-0.83; and adjusted OR, 0.90; 95% CI, 0.84-0.96, respectively). Relative to phase 3 trials, earlier-and later-phase trials were also less likely to report use of blinding (ad- will engender much-needed debate about clinical trial methodologies and funding allocation.
CLINICAL TRIALS REGISTERED IN CLINICALTRIALS.GOV
Many of the differences noted in the present study have been identified before and likely represent variation in appropriate approaches for particular diseases. Reviews of samples from the literature in 1980 23 and 2000 24 raised similar questions, for which this report provides a contemporary and more comprehensive sample. Despite concerns previously articulated by Meinert et al 23 and Chan and Altman 24 -concerns that included a relatively high prevalence of clinical trials with inadequate sample sizes and insufficiently described methodologies-disparities still remain across specialties. This in turn raises questions about why such heterogeneity persists, whether the portfolio documented by this analysis suffices to address gaps in evidence, and the reasons underlying differences in trial methodology. It is particularly important to identify cases in which such methodological differences lack adequate scientific justification, as they may present an opportunity for improving the public health through adjustments to research investment strategies and methods.
Implications for Policy and Strategy
The fact that 50% of interventional studies registered from October 2007 to September 2010 by design include fewer than 70 participants may have important policy implications. Small trials may be appropriate in many cases (eg, earlier-phase drug evaluations, or investigations of biological or behavioral mechanisms, rather than clinical outcomes). Particularly in oncology, there is a growing sense that small trials based on genetics or biomarkers can yield definitive results. 25 However, small trials are unlikely to be informative in many other settings, such as establishing the effectiveness of treatments with modest effects and comparing effective treatments to enable better decisions in practice. [26] [27] [28] Preliminary observations suggest that many small clinical trials were designed to enroll more participants, raising questions about their ultimate power (D. A. Zarin, MD, written communication, March 28, 2012) , but an accurate depiction of these issues requires a more in-depth analysis. These findings raise important issues that should be addressed by detailed, specialtyoriented assessments of the utility of the large number of small trials.
A comprehensive collection of all clinical trials on a global basis would enable the most effective examination of evidence to support medical decisions. The effect of the globalization of clinical research has been debated, [29] [30] [31] [32] and emerging evidence of differential regional involvement as a function of therapeutic area also raises questions relevant to policy and strategy. Although the World Health Organization (WHO) provides a portal for many trial registries from around the world, unacknowledged duplicate entries make it difficult to determine a unique list of clinical trials; in addition, the overall data set is not available for electronic download, rendering the data unavailable for aggregate analysis.
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Attention to standards for nondrug interventions (eg, biologics, devices, and procedures) as well as study design would also enhance the ability to describe and understand the clinical trials enterprise. 34 Indeed, as Devereaux and colleagues 35 point out, concepts as fundamental as blinding are shrouded in terminological confusion and ambiguity. Furthermore, lack of clarity surrounding the naming of devices and biolog-ics makes examination of specific medical technologies difficult.
Although the industry is the lead sponsor in only about 36% of interventional trials in this study, these accounted for 59% of all trial participants. Further analysis of trials in each specialty may help elucidate this complex mix of funding, trial size, and location so that policies might be enacted to improve the responsiveness of trials to the needs of public health and the overall research community.
Methodological differences across therapeutic areas are also of interest. The greater focus on earlier-phase trials and biomarker-based personalized medicine 25 may explain some of the differences in approach evident with oncology trials, but substantial differences in the use of randomization and blinding across specialties persist after adjustment for phase, raising fundamental questions about the ability to draw reliable inferences from clinical research conducted in that arena.
The reporting of use of a DMC is an optional data element within the ClinicalTrials.gov registry. The appropriate criteria for determining when a DMC is useful or required remain controversial. Yet the heterogeneity observed by trial phase, disease category, and lead sponsor category in this study (eg, industry vs government sponsorship) may represent an opportunity for mutual learning and compromise among disparate views. The trend toward increased reporting of use of DMCs over time in this study is notable, but clear policies would be useful to those researchers designing trials. For example, many different arrangements can be made for monitoring safety in clinical trials, and the current data only reflect the presence of a typical, well-defined DMC.
Limitations
Several limitations of our study should be noted. First, ClinicalTrials.gov does not includeallclinicaltrials.WithintheUnited States, legal requirements for registration do not include phase 1 trials, trials not involving a drug or device, and trials not under US jurisdiction. Also, although many trialists from other countries use ClinicalTrials.gov to satisfy ICMJE registration requirements, 7 other registries aroundtheworldmaybeused. 10 However, ClinicalTrials.gov still accounts for more than80%ofallclinicalstudiesintheWHO portal, as based on comparisons of the number of clinical studies appearing in the ClinicalTrials.gov registry divided by the number of unique studies appearing in the WHO portal.
Second, there have been changes over time in the data collected, the definitions used, and the rigor with which missing data are pursued. As described in the "Methods" section, some data elements were either missing or unavailable because of practical or logistical limitations. Some of these issues can be addressed by focused analyses in which ancillary data sets are created or review of primary protocols and studies is done. In addition, the potential for serious sanctions for incomplete data under the FDAAA may have improved data collection for those fields in recent years. As noted earlier, we used the study type field from the ClinicalTrials.gov registry to identify interventional studies; however, we did not perform additional manual screening to identify and exclude possibly misclassified observational studies.
Third, the need for a standard ontology to describe clinical research remains a pressing concern. Current definitions were developed to help individuals find particular trials or were legally mandated without necessarily involving experts or allowing time for testing. Consequently, some data remain ambiguous, complicating efforts to combine and analyze results in a given therapeutic area or across areas. For example, the terms interventional trial and clinical trial are critical for distinguishing purely observational studies from those that assign participants to an interventional therapy. Further refinement of this definition 9 could be helpful to those interested in differentiating high-risk invasive interventions from low-risk interventions or distinguishing specific types of behavioral, drug, or device interventions.
CONCLUSIONS
The clinical trials enterprise as revealed by the contents of ClinicalTrials.gov is dominated by small clinical trials and contains significant heterogeneity in methodological approaches, including the use of randomization, blinding, and DMCs. Our analysis raises questions about the best methods for generating evidence, as well as the capacity of the clinical trials enterprise to supply sufficient amounts of highquality evidence needed to ensure confidence in guideline recommendations. Given the deficit in evidence to support key decisions in clinical practice guidelines 11, 12 as well as concerns about insufficient numbers of volunteers for trials, 36 the desire to provide high-quality evidence for medical decisions must include consideration of a comprehensive redesign of the clinical trial enterprise.
